Mental Health is Focus of New High-Potential Anti-Depression Project from MaRS Innovation and the Centre for Addiction and Mental Health Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many...

Fibrocor, a MaRS Innovation portfolio company, announces deal with Galapagos Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation...

LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN) Toronto, ON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec.   The project aims to develop a...

EVOTEC AG AND MARS INNOVATION ANNOUNCE FIRST FUNDED PROJECT UNDER LAB150 BRIDGE Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have...

MARS INNOVATION AND EVOTEC AG ESTABLISH ACADEMIC BRIDGE “LAB150” IN TORONTO Toronto, Sept. 14, 2017 (GLOBE NEWSWIRE) -- MaRS Innovation (“MI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the launch of “LAB150”.  This...